Meros Investment Management LP bought a new stake in shares of Simulations Plus, Inc. (NASDAQ:SLP – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 339,242 shares of the technology company’s stock, valued at approximately $6,184,000. Simulations Plus comprises approximately 2.5% of Meros Investment Management LP’s investment portfolio, making the stock its 17th biggest holding. Meros Investment Management LP owned 1.68% of Simulations Plus at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Simulations Plus in the 2nd quarter valued at $25,000. Quarry LP bought a new position in Simulations Plus in the 3rd quarter valued at $28,000. Caitong International Asset Management Co. Ltd grew its position in Simulations Plus by 460.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,038 shares of the technology company’s stock valued at $92,000 after acquiring an additional 4,139 shares during the last quarter. US Bancorp DE grew its position in Simulations Plus by 32.5% in the 3rd quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after acquiring an additional 1,513 shares during the last quarter. Finally, CWM LLC grew its position in Simulations Plus by 160.2% in the 4th quarter. CWM LLC now owns 5,480 shares of the technology company’s stock valued at $100,000 after acquiring an additional 3,374 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.
Simulations Plus Trading Up 0.3%
SLP opened at $16.37 on Tuesday. Simulations Plus, Inc. has a 12-month low of $11.09 and a 12-month high of $21.01. The business’s fifty day simple moving average is $14.88 and its 200-day simple moving average is $15.56. The company has a market capitalization of $330.67 million, a price-to-earnings ratio of -5.23 and a beta of 1.32.
Analyst Ratings Changes
Several equities analysts have commented on SLP shares. Weiss Ratings raised Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, TD Cowen cut their price objective on Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, April 10th. Two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $21.50.
Check Out Our Latest Research Report on SLP
About Simulations Plus
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
See Also
- Five stocks we like better than Simulations Plus
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP – Free Report).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
